Becton, Dickinson and Company (NYSE:BDX - Get Free Report) had its price target increased by stock analysts at Argus from $220.00 to $230.00 in a report issued on Monday,MarketScreener reports. Argus' price target would indicate a potential upside of 22.81% from the company's current price.
Several other equities analysts have also weighed in on BDX. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average target price of $213.30.
Check Out Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Stock Performance
BDX stock traded down $1.10 during midday trading on Monday, reaching $187.27. The stock had a trading volume of 2,750,943 shares, compared to its average volume of 1,535,837. The stock has a market cap of $53.68 billion, a PE ratio of 33.68, a P/E/G ratio of 1.51 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a fifty day simple moving average of $187.65 and a two-hundred day simple moving average of $190.16. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Insider Buying and Selling at Becton, Dickinson and Company
In related news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock worth $551,536 in the last 90 days. Company insiders own 0.36% of the company's stock.
Institutional Investors Weigh In On Becton, Dickinson and Company
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after buying an additional 27,581 shares during the last quarter. FORA Capital LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $3,458,000. Foster Victor Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $6,406,000. Finally, GAMMA Investing LLC boosted its stake in Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares during the period. Institutional investors own 86.97% of the company's stock.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
